BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
Genmab and its CEO Jan van de Winkel will fight to the last breath in in its current dispute with US partner Janssen. At least, that is the impression you get from speaking to the Dutch bussinessman.
"Sometimes in life you just need to stand up straight and fight for what you believe is morally and ethically right. This is what we are doing here. We are a very ethical company, and I believe that we have the right to defend ourselves," says van de Winkel.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
Chief Physician - Clinical Innovation Centre, Novo Nordisk 
Clinical Supply Coordinator - Klifo 
Employee for regulatory department 
Clinical Trial Manager - Genmab 
Chemist responsible for validation and qualification for Laboratory Automation Development 
Associate Medical Director, Translational Medicine - Y-mAbs Therapeutics 
Clinical Supply Manager/Specialist - Lundbeck 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen 
(Senior) Regulatory Science Specialist - IWA Consulting 
Regulatory affairs life cycle specialist